Real-world study finds standalone travoprost intracameral implant significantly reduces IOP and medication burden for glaucoma
At the American Society of Cataract and Refractive Surgery Annual Meeting, Savak Teymoorian, MD, of Harvard Eye Associates, spoke about real-world findings from his practice that indicated that standalone travoprost intracameral implant significantly reduced intraocular pressure.
Savak Teymoorian, MD:
We have the pleasure of taking care of patients with ocular hypertension and open-angle glaucoma, but we’re always striving to find ways of doing things better. Now, all the glaucoma studies show that there’s 2 key things we need to do to better serve our patients in order to get their pressure down. You have to bring the pressure down, you have to keep the pressure down. It’s easy to bring the pressure down at the beginning because you’re motivated, the patient’s motivated. Maybe you can start them on some eye drops, and they do okay with that. But in the long-term, using glaucoma eye drops, much like try to establish a good habit of going to the gym, is difficult. Simply, patients run into problems with their drops. Common barriers are costs, side effects, remembering them, and putting them in.
What I wanted to do with you is to share my real-world experience of a travoprost intracameral implant. What this implant does is it allows sustained release of travoprost oil over a period of time, and that allows us to deliver medication to the patient’s eye inside of the eye without the patient having to put so many drops onto their eyes. Now, if you look at their studies, the previous studies are out to 3 months. I wanted to see in my actual patients how long does it last for and how effective it is.
In the study that I did, we looked at 65 eyes in a retrospective way. They were my patients only, and of these eyes with open-angle glaucoma or ocular hypertension, we wanted to assess at 6 months how did their intraocular pressures do. You’ll see a statistically significant reduction in their IOPs from baseline, which started from about 20 and went down to about 14.2. But more importantly, you see the reliance on eye drops also going down statistically as well, too. The patients are less reliant on drops to bring their pressure down. Now I end up being happy because the pressure is down. Patient is happy because they don’t have to use so many eye drops. It’s a win-win situation.
Thank you everybody. I appreciate your time.
Related Content
